ImmunityBio’s (IBRX) “Buy” Rating Reaffirmed at D. Boral Capital

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a note issued to investors on Monday,Benzinga reports. They currently have a $30.00 price objective on the stock.

A number of other research firms also recently commented on IBRX. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd. BTIG Research started coverage on shares of ImmunityBio in a research note on Friday, January 10th. They issued a “buy” rating and a $6.00 price objective for the company.

ImmunityBio Stock Up 1.4 %

IBRX stock traded up $0.05 during midday trading on Monday, hitting $3.22. The company’s stock had a trading volume of 879,528 shares, compared to its average volume of 6,170,517. ImmunityBio has a 12 month low of $2.28 and a 12 month high of $10.53. The company has a 50 day moving average of $3.51 and a two-hundred day moving average of $4.08. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -3.54 and a beta of 0.86.

Institutional Trading of ImmunityBio

A number of hedge funds have recently added to or reduced their stakes in the business. Captrust Financial Advisors purchased a new stake in shares of ImmunityBio in the 3rd quarter worth approximately $41,000. Mutual Advisors LLC purchased a new stake in ImmunityBio during the fourth quarter worth $41,000. Virtu Financial LLC purchased a new position in shares of ImmunityBio in the 3rd quarter valued at $51,000. Algert Global LLC bought a new position in ImmunityBio in the second quarter worth about $86,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock worth $99,000 after buying an additional 4,545 shares during the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.